Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are a novel class of oral hypoglycemic drugs used for the management of type 2 diabetes mellitus (T2DM). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.